Skip to main content
OpenTrials
Completed

NCT Number: NCT04779892

The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety

A phase 1, Randomized, Double-blind, Parallel group, Sing-dose study to compare the Pharmacokinetics and Safety of CMAB008 and Remicade in healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Shanghai Xuhui Central Hospital

Shanghai, Shanghai Municipality, 200031, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy subject (male) between the ages of 18 and 45 years.
  • Subject with a body weight of ≥50 kg and ≤ 80 kg and a BMI between 19.0~26.0 kg/m2 (both inclusive);
  • Healthy as determined by pre-study medical history, physical examination, vital signs and 12-lead electrocardiogram;

Exclusion criteria

  • Those who have surgered 4 weeks before signing the informed consent;
  • Those with mental, respiratory, cardiovascular, digestive, urinary, reproductive, skeletal and motor, blood, endocrine, nervous and other system diseases, or those with any previous immune diseases;
  • Those who have received any drug treatment (including prescription drugs, over-the-counter drugs, biological products, Traditional Chinese medicine, vitamins, dietary supplements, etc.) and health care products within 4 weeks before signing the informed consent;
  • Those who accepted biological drugs within 6 months before signing the informed consent, or accepted the TNF monoconal antibody drugs;
  • Any one of HIV antibody, HBsAg, HBeAg, HBcAg, HCV antibody and Treponema pallidum antibody is positive;
  • Either T cell immunospot test (T-SPOT) or antinuclear antibody is positive;
  • Those who have infected within 30 days before administration, or serious infection associated with hospitalisation and/or which required inrravenous antibiotics within 3 months before administration.
  • Vaccinated within 30 months before signing the informed conset, or plan to vaccinate during the trail;
  • Those who have used soft drugs within 3 months prior to signing the informed consent or hard drugs within 1 year prior to the trail; those who have positive drug abuse test results;
  • Those who drinking too much tea, coffee and/or caffeinated beverages (more than 8 cups, 250ml per cup) every day;
  • Those who have a blood donation history of 400 ml within 3 months, or 200 ml within 1 month;
  • Those who have a history of drug or food allergy, or are known to be allergic to any component of the test drug or latex, etc.
  • Those who are addicted to smoking or smoke more than 10 cigarettes per day on average within 6 months before signing the informed consent;
  • Alcoholics or regular drinkers within 3 months before the trail, i.e. those who drink more than 14 units of alcohol per week (14 bottles of 360 ml beer or 630 ml spirits with 40% alcohol), or whose alcohol breath test is positive;
  • Those who plan to donate sperm within 6 months after the adminstration of the test drug;

Treatment and study plan

Infliximab

Drug

100mg/vial

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours After the Single Infusion of CMAB008/Remicade

    Time frame: up to 1680 hours

Secondary outcomes

  1. Maximum Concentration of Infliximab After the Single Infusion of CMAB008/Remicade

    Time frame: up to 1680 hours

  2. Time of Maximum Concentration of Infliximab After the Single Infusion of CMAB008/Remicade

    Time frame: up to 1680 hours

  3. Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time After the Single Infusion of CMAB008/Remicade

    Time frame: up to 1680 hours

  4. Total Frequency of AE/SAE Within the Whole Time of the Study

    Time frame: up to 1680 hours

  5. Percentage of Patients in Whom Bind or Neutralizing Antibodies to Infliximab Were Detected

    Time frame: up to 1680 hours

Sponsors and collaborators

Lead sponsor

Taizhou Mabtech Pharmaceutical Co.,Ltd

Industry

Registry information

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Mar 3, 2021
Registry last updated
Oct 11, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.